| Short Description : | Recombinant-SARS-COV-2 NSP7&NSP8-C-His protein was developed in e.coli using the region Ser1-Gln83. For use in research applications. |
| Host: | E.coli |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: | < 1 EU/Mu g of the protein by LAL method. |
| Immunogen: | SARS-COV-2 NSP7&NSP8 Protein is expressed from E.coil with His tag at the C-terminal.；It contains Ser1-Gln83 (NSP7) &Ala1-Gln198 (NSP8). |
| Immunogen Region: | Ser1-Gln83 |
| Immunogen Sequence: | SKMSDVKCTSVVLLSVLQQL RVESSSKLWAQCVQLHNDIL LAKDTTEAFEKMVSLLSVLL SMQGAVDINKLCEEMLDNRA TLQAIASEFSSLPSYAAFAT AQEAYEQAVANGDSEVVLKK LKKSLNVAKSEFDRDAAMQR KLEKMADQAMTQMYKQARSE DKRAKVTSAMQTMLFTMLRK LDNDALNNIINNARDGCVPL NIIPLTTAAKLMVVIPDYNT YKNTCDGTTFTYASALWEI |
| Background | The crystal structure of the metabolite of remdesivir (Monophosphate of GS-441524) and NSP12-NSP8-NSP7 of SARS CoV-2 virus was recently reported. The crystal structures of ADP-Ribose or AMP and NSP3 of SARS CoV-2 virus were also released, recently. The crystal structure of NSP3 of SARS CoV-2 virus as an alternative binding site of AMP or ADP-ribose to treat COVID-19. |
Information sourced from Uniprot.org